Gaku Nakazawa

Learn More
BACKGROUND Late stent thrombosis (LST) after Cypher and Taxus drug-eluting stent placement has emerged as a major concern. Although the clinical predictors of LST have been reported, specific morphological and histological correlates of LST remain unknown. METHODS AND RESULTS From a registry totaling 81 human autopsies of drug-eluting stents, 46 (62(More)
OBJECTIVES Human coronary bare-metal stents (BMS) and drug-eluting stents (DES) from autopsy cases with implant duration >30 days were examined for the presence of neointimal atherosclerotic disease. BACKGROUND Neointimal atherosclerotic change (neoatherosclerosis) after BMS implantation is rarely reported and usually occurs beyond 5 years. The incidence(More)
OBJECTIVES We investigated the frequency of the noncardiac findings in cardiac imaging with multidetector computed tomography (MDCT). BACKGROUND Multidetector computed tomography is an accepted new tool to evaluate the heart. In cardiac MDCT scans, organs other than the heart are also irradiated, but usually not assessed. METHODS A total of 503 patients(More)
Although rare, stent thrombosis remains a severe complication after stent implantation owing to its high morbidity and mortality. Since the introduction of drug-eluting stents (DES), most interventional centers have noted stent thrombosis up to 3 years after implantation, a complication rarely seen with bare-metal stents. Some data from large registries and(More)
BACKGROUND The long-term safety of drug-eluting stents (DES) for acute myocardial infarction (AMI) remains uncertain. Using autopsy data, we evaluated the pathological responses of the stented segment in patients treated with DES for AMI and compared with patients with stable angina. METHODS AND RESULTS From the CVPath Registry of 138 DES autopsies, we(More)
OBJECTIVES The purpose of this study was to assess trends in endothelial coverage and recovery among leading polymer-based drug-eluting stents (DES). BACKGROUND Autopsy studies of human U.S. Food and Drug Administration (FDA)-approved DES implanted coronary arteries suggest that complications of late stent thrombosis are associated with incomplete(More)
BACKGROUND Stent fracture is one of the possible causes of restenosis after sirolimus-eluting stents (SES) implantation. The aim of our study was to evaluate the prevalence and clinical impact of coronary stent fracture after SES implantation. METHODS From our prospective institutional database, 280 patients were treated solely with SES from August 2004(More)
Polymer-based sirolimus- (Cypher) and paclitaxel-eluting (Taxus) drug eluting stents have become the treatment of choice for patients with symptomatic coronary artery disease undergoing percutaneous coronary intervention (PCI). Although these stents reduce rates of restenosis compared with bare metal stents (BMS), late thrombosis, a life threatening(More)
OBJECTIVES The aim of this study was to perform pathologic assessment on stent fracture. BACKGROUND Clinically, stent fracture has been reported in 1% to 2% of patients after drug-eluting stent (DES) implantation. METHODS High-contrast film-based radiographs of 177 consecutive lesions from the CVPath DES autopsy registry were reviewed. Stent fracture(More)
OBJECTIVES In this study, we hypothesized that an antihuman-CD34 antibody immobilized on the surface of commercially available sirolimus-eluting stents (SES) could enhance re-endothelialization compared with SES alone. BACKGROUND Previous experience with antihuman-CD34 antibody surface modified Genous stents (GS) (OrbusNeich Medical, Fort Lauderdale,(More)